Major Depressive Disorder

Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.

New prospective data show more adult patients achieved clinical response with ketamine than the historic standard ECT over a 6-month regimen.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

Dr. Levine talks with Marketa Wills, MD, about the role of the payer in medicine.

An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.

There was an increase in depression in the cystic fibrosis group, as well as an increase in anxiety in cystic fibrosis caregivers during the pandemic.

Scores for the 20-Item Symptom Checklist improved from baseline over gestation in the interpersonal psychotherapy cohort, but not in the enhanced usual care group.

The results show depressive disorders in the first cohort were associated with a nearly 4-fold higher risk of depressive disorders in the spousal cohort.

State adoption of both SNAP eligibility policies, where the state eliminates the asset test and increases the income limit resulted in decreases in the rates of past-year major depressive episodes, mental illness, serious mental illness, and suicidal ideation.

Electroconvulsive therapy was superior to ketamine in a sensitivity analysis of methodologically stronger trials and also was better in study-defined response and remission for patients with major depressive episodes.

There was also significantly greater reductions in anxiety, Afghan-cultural distress symptoms, and psychiatric difficulties compared to the treatment as usual group.

There was a lower probability of initiating psycholeptics and having postpartum psychiatric emergencies in the early discontinuer and late discontinuer groups compared to the continuers.

Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.

The results show 28.9% of the aripiprazole augmentation group achieved remission, compared to 28.2% of the bupropion augmentation group and 19.3% of the bupropion switch group.

The results from a Bayesian reinforcement learning model showed the antidepressant placebo trial-wise expectancies were updated by composite learning signals multiplexing sensory evidence and trial-wise mood.

According to the data, sleep quality, fatigue, and social well-being contribute to depression among young adults with autism, with social well-being being a significant predictor of depression over a 2-year period.

Exposure to maternal, paternal, or full sibling major depression was associated with a two-fold higher risk of major depression for men.

Andrew J Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, comment on the need to improve awareness around depressive disorders and break the stigma of mental health treatment.

Experts in psychiatry review emerging mechanisms of action in the treatment landscape of MDD.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, share their approach to treatment-resistant depression.

Drs Andrew J. Cutler, Gregory Mattingly, and Sagar V. Parikh discuss the treatment of MDD in female patients who are pregnant or plan to become pregnant.

The same risk was not found for offspring of fathers with primary immunodeficiencies.

Experts in psychiatry review factors to consider when deciding to switch or augment treatment in major depressive disorder [MDD].

Drs Andrew J Cutler, Gregory Mattingly, and Sagar V Parikh provide advice to clinicians on monitoring treatment in major depressive disorder.

Experts in psychiatry provide insight into treating episodic vs chronic major depressive disorder and factors they consider when approaching treatment selection.